FLAVONE ACETIC-ACID AND PLASMA-PROTEIN BINDING

被引:7
|
作者
BRODFUEHRER, J
VALERIOTE, F
CHAN, K
HEILBRUN, L
CORBETT, T
机构
[1] Division of Hematology and Oncology, Department of Internal Medical, Wayne State University, Detroit, 48 202, MI
关键词
D O I
10.1007/BF00689272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA to plasma protein was significantly greater in both healthy human and cancer patient plasma than in mouse plasma. Plasma from patients with cancer bound on the average less FAA than did healthy patient plasma. The concentration of albumin in the plasma varied between healthy humans, cancer patients, and mice, being 5.3±0.7, 4.7±0.8, and 3.9±0.3 g/100 ml, respectively. The protein binding of FAA was found to be dependent on the plasma albumin concentration, but albumin concentration alone was not adequate for the accurate prediction of the percentage of FAA protein bound. Scatchard plots indicated that healthy human plasma had a greater number of high-affinity binding sites than did mouse plasma. FAA binds at the indolebenzodiazepine binding area on albumin and can be displaced from this site by salicylic acid and clofibric acid, but only at supratherapeutic concentrations. Our results indicate that alterations in plasma albumin could contribute to a variable effect with FAA. Therefore, the influence of serum albumin concentration and the nonlinearity of FAA protein binding should be considered in assessment of the appropriateness of a dose schedule for FAA. © 1990 Springer-Verlag.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 50 条
  • [1] PLASMA-PROTEIN BINDING OF FLAVONE ACETIC-ACID (FAA) DURING CONTINUOUS INTRAVENOUS-INFUSION TO CANCER-PATIENTS
    STAUBUS, AE
    GREVER, MR
    MALSPEIS, L
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 188 - 188
  • [2] SATURABLE ELIMINATION AND SATURABLE PROTEIN-BINDING ACCOUNT FOR FLAVONE ACETIC-ACID PHARMACOKINETICS
    RELLING, MV
    EVANS, RR
    GROOM, S
    CROM, WR
    PRATT, CB
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (06): : 639 - 651
  • [3] IMMUNOLOGICAL EFFECTS OF FLAVONE ACETIC-ACID
    TRIOZZI, PL
    RINEHART, JJ
    MALSPEIS, L
    YOUNG, DC
    GREVER, MR
    CANCER RESEARCH, 1990, 50 (20) : 6483 - 6485
  • [4] FLAVONE ACETIC-ACID - A NONLINEAR PHARMACOKINETIC MODEL
    GOUYETTE, A
    KERR, DJ
    KAYE, SB
    SETANOIANS, A
    CASSIDY, J
    BRADLEY, C
    FORREST, G
    SOUKOP, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1988, 22 (02) : 114 - 119
  • [5] FLAVONE ACETIC-ACID INDUCES A COAGULOPATHY IN MICE
    MURRAY, JC
    SMITH, KA
    THURSTON, G
    BRITISH JOURNAL OF CANCER, 1989, 60 (05) : 729 - 733
  • [6] FLAVONE ACETIC-ACID - PRECLINICAL AND CLINICAL ACTIVITY
    KERR, DJ
    KAYE, SB
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (09): : 1271 - 1272
  • [7] FLAVONE ACETIC-ACID FROM LABORATORY TO CLINIC AND BACK
    BIBBY, MC
    DOUBLE, JA
    ANTI-CANCER DRUGS, 1993, 4 (01) : 3 - 17
  • [8] FLAVONE ACETIC-ACID - IS TUMOR ENDOTHELIUM A PRIMARY TARGET
    MURRAY, JC
    THURSTON, G
    SMITH, KA
    DENEKEMP, J
    STERN, D
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 516 - 516
  • [9] INHIBITION OF ANTITUMOR EFFECTS OF FLAVONE ACETIC-ACID BY CORTISONE
    CHING, LM
    JOSEPH, WR
    BAGULEY, BC
    ANTICANCER RESEARCH, 1993, 13 (04) : 1139 - 1141
  • [10] PHASE-I PHARMACOKINETICS OF FLAVONE ACETIC-ACID
    TRANCHAND, B
    NASRI, F
    MINUIT, M
    CLAVEL, M
    GUASTALLA, JP
    GAMAND, S
    ARDIET, C
    BULLETIN DU CANCER, 1989, 76 (08) : 871 - 874